Loading this company
Parabilis Medicines, Inc.
PBLSPrices in USD
TickerWorth ScoreF35/100
What we think
Priced above our one model’s value of $8.80.
Price
$25.95USD up +$0.06 (+0.23%)
Quoted · Prices are delayed.
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
One model only, on today’s numbers
$8.80
Led by discounted cash flow (DCF) · Steady cash-flow business
Price $25.95Priced · Prices are delayed.
Changing the inputs, and every lens with its working, is part of Pro. See plans
Is it a good business?
- Valuation50 out of 100
- Financial health67 out of 100
- Past performance0 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$41.75 across 4 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 145 people.
Key stats
52-week range$24.51–$42.49
- Open
- $25.73
- Day high
- $26.44
- Day low
- $24.80
- Previous close
- $25.89
- Volume
- 954,610 · 1.32× avg
- Average volume
- 723,877
- Market cap
- $3,110,566,912.00
- P/E (TTM)
- —
- Earnings per share
- −$9.51
- Beta
- —
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Issued a public disclosure (Reg FD)
- Changed leadership or its board
- Changed leadership or its board
- Reported quarterly or annual results
- Signed a material agreement
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- RA CAPITAL MANAGEMENT, L.P.Open-market buy · $1,406,632.50
- RA CAPITAL MANAGEMENT, L.P.Open-market buy ·
Not investment advice. TickerWorth Score is a model output.